Nivobotulinumtoxin A is under clinical development by Medytox and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Nivobotulinumtoxin A’s likelihood of approval (LoA) and phase transition for Axillary Hyperhidrosis took place on 06 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Nivobotulinumtoxin A Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Nivobotulinumtoxin A overview

NivobotulinumtoxinA/Botulinum Toxin Type A (Meditoxin/Botulift/ Coretox) is a neuromuscular agent which is produced from fermentation of Hall strain Clostridium botulinum type A. It is formulated as powder for solution for intramuscular route of administration. NivobotulinumtoxinA/ is indicated for the treatment of benign essential blepharospasm, Hemifacial spasm, cerebral palsy and upper limb muscle spasticity.

MT-10109 (nivobotulinumtoxinA) is under development for the treatment of cervical dystonia (neck dystonia, spasmodic torticollis), benign masseteric hypertrophy, primary axillary hyperhidrosis, unspecified musculoskeletal disorders and benign essential blepharospasm. It is administered through intradermal, intradetrusor routes. It was also under development for the treatment of neuropathic pain in patients with diabetic peripheral polyneuropathy, migraine, overactive bladder.

Medytox overview

Medytox is a pharmaceutical company that develops, manufactures and markets biopharmaceutical products. The company offering products includes botulinum toxin, hyaluronic acid filler and medical device. its botulinum toxin type a product comprises neuronox, innotox and coretox. Medytox hyaluronic acid filler provides neuramis an potenfill. The company also offer neurakin cream. The company provide comfortdual, a medical device for tissue coagulation by using high-frequency current. It has operations with manufacturing plants, research and development centers and joint venture companies in Taiwan, China, Hong Kong, Japan and Thailand. Medytox is headquartered in Cheongju-si, Chungcheongbuk-do, South Korea.

Quick View Nivobotulinumtoxin A LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Nivobotulinumtoxin A
Administration Pathway
  • Intradermal
  • Intramuscular
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Genito Urinary System And Sex Hormones
  • Musculoskeletal Disorders
  • Ophthalmology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.